Carisma Therapeutics

84 articles about Carisma Therapeutics

• Carisma Therapeutics to Present at Upcoming April 2024 Conferences

  4/3/2024

  Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that it will present at the following upcoming conferences.

• Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

  4/1/2024

  Carisma Therapeutics Inc. today reported financial results for the fourth quarter, and full year ended December 31, 2023, and provided a business update.

• Carisma Therapeutics Announces Changes to its Board of Directors

  4/1/2024

  Carisma Therapeutics Inc. today announced the appointment of John Hohneker, M.D. to the Board of Directors.

• Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

  3/21/2024

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced its upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5-10, 2024, in San Diego, California.

• Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference

  2/28/2024

  Carisma Therapeutics Inc. today announced that Steven Kelly , President and Chief Executive Officer, will participate in the TD Cowen 44th Annual Health Care Conference.

• Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  12/21/2023

  Carisma Therapeutics Inc. today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024.

• First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

  12/14/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA).

• Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

  11/28/2023

  Carisma Therapeutics Inc today announced the clearance of its Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA) for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2).

• Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference

  11/22/2023

  Carisma Therapeutics Inc. today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29 at 2:35 pm ET.

• Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

  11/9/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2023, and highlighted recent business updates.

• Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

  10/31/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna.

• Carisma Therapeutics to Present at Upcoming Investor Conferences

  9/5/2023

  Carisma Therapeutics Inc. today announced that it will present at several upcoming investor conferences.

• Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit

  9/1/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, will present findings today at the 8th Annual CAR-TCR Summit from its Phase 1 clinical trial of the Company's lead product candidate, CT-0508.

• Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023

  8/24/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at two healthcare industry conferences in September 2023.

• Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

  8/10/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended June 30, 2023, and highlighted recent business updates.

• Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors

  6/28/2023

  Carisma Therapeutics Inc. announced that the first patient has been dosed in its Phase I clinical trial that will test the safety and tolerability of the Company's lead product candidate, CT-0508.

• Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes

  6/26/2023

  Carisma Therapeutics Inc. today announced that the Company will join the Russell 2000 ® , Russell 3000 ® and Russell Microcap ® Indexes following the conclusion of the 2023 Russell indexes annual reconstitution, effective upon the U.S. markets open today, June 26, 2023.

• Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources

  6/14/2023

  Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced leadership updates.

• Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023

  6/5/2023

  Carisma Therapeutics Inc. today announced that the Company will present at several investor conferences in June 2023.

• Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023

  5/30/2023

  Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several healthcare industry conferences in June 2023.